NO20071160L - Use of a selective estrogen receptor modulator for the preparation of a pharmaceutical composition for use in a method for the treatment or prevention of androgen deficiency - Google Patents

Use of a selective estrogen receptor modulator for the preparation of a pharmaceutical composition for use in a method for the treatment or prevention of androgen deficiency

Info

Publication number
NO20071160L
NO20071160L NO20071160A NO20071160A NO20071160L NO 20071160 L NO20071160 L NO 20071160L NO 20071160 A NO20071160 A NO 20071160A NO 20071160 A NO20071160 A NO 20071160A NO 20071160 L NO20071160 L NO 20071160L
Authority
NO
Norway
Prior art keywords
pharmaceutical composition
androgen deficiency
estrogen receptor
receptor modulator
selective estrogen
Prior art date
Application number
NO20071160A
Other languages
Norwegian (no)
Inventor
Risto Lammintausta
Taru Blom
Janne Komi
Original Assignee
Hormos Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20041216A external-priority patent/FI20041216A0/en
Application filed by Hormos Medical Ltd filed Critical Hormos Medical Ltd
Publication of NO20071160L publication Critical patent/NO20071160L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Abstract

Foreliggende oppfinnelse angår anvendelse av en selektiv østrogenreseptormodulator, eller en isomer, isomerblanding, metabolitt eller et farmasøytisk akseptabelt salt derav for fremstilling av et farmasøytisk preparat for anvendelse i en fremgangsmåte for behandling eller forebygging av androgenmangel eller sykdommer og forstyrrelser forårsaket av androgenmangel hos et mannlig individ.The present invention relates to the use of a selective estrogen receptor modulator, or an isomer, isomer composition, metabolite or a pharmaceutically acceptable salt thereof, for the manufacture of a pharmaceutical composition for use in a method of treating or preventing androgen deficiency or diseases and disorders caused by a male androgen deficiency. .

NO20071160A 2004-09-03 2007-03-01 Use of a selective estrogen receptor modulator for the preparation of a pharmaceutical composition for use in a method for the treatment or prevention of androgen deficiency NO20071160L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60690704P 2004-09-03 2004-09-03
FI20041216A FI20041216A0 (en) 2004-09-21 2004-09-21 A method of treating or preventing an androgen deficiency
PCT/FI2005/000333 WO2006024689A1 (en) 2004-09-03 2005-07-20 Use of a selective estrogen receptor modulator for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency

Publications (1)

Publication Number Publication Date
NO20071160L true NO20071160L (en) 2007-05-25

Family

ID=35999733

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071160A NO20071160L (en) 2004-09-03 2007-03-01 Use of a selective estrogen receptor modulator for the preparation of a pharmaceutical composition for use in a method for the treatment or prevention of androgen deficiency

Country Status (10)

Country Link
EP (1) EP1786408A4 (en)
JP (1) JP2008511615A (en)
KR (1) KR20070059110A (en)
AU (1) AU2005279178A1 (en)
BR (1) BRPI0514701A (en)
CA (1) CA2578852A1 (en)
MX (1) MX2007002606A (en)
NO (1) NO20071160L (en)
RU (1) RU2007112114A (en)
WO (1) WO2006024689A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101510646B1 (en) 2007-02-14 2015-04-10 호르모스 메디칼 리미티드 Method for the preparation of therapeutically valuable triphenylbutene derivatives
WO2008157335A2 (en) * 2007-06-13 2008-12-24 Quatrx Pharmaceuticals Company Methods for the treatment of erectile dysfunction using fispemifene
CA2800673A1 (en) 2010-06-10 2011-12-15 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
US9187460B2 (en) 2011-12-14 2015-11-17 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
US9744177B2 (en) * 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
US9975832B2 (en) 2014-12-29 2018-05-22 Olon S.P.A. Process for the preparation of ospemifene and fispemifene
WO2023175010A1 (en) * 2022-03-15 2023-09-21 Centre D'etude Des Cellules Souches (Cecs) Use of bazedoxifene for increasing muscle survival

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL120262A (en) * 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
US6632447B1 (en) * 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
TW593256B (en) * 1999-11-16 2004-06-21 Hormos Medical Oy Ltd Triphenylalkene derivatives and their use as selective estrogen receptor modulators
CO5271697A1 (en) * 2000-01-12 2003-04-30 Pfizer Prod Inc COMPOSITIONS AND PROCEDURES FOR THE TREATMENT OF AFFECTIONS THAT RESPOND TO AN INCREASE OF TESTOSTERONE
US6391920B1 (en) * 2000-05-26 2002-05-21 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
US7067557B2 (en) * 2000-05-26 2006-06-27 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
DK1460969T3 (en) * 2001-11-29 2008-09-01 Gtx Inc Prevention and treatment of androgen deprivation caused by osteoporosis

Also Published As

Publication number Publication date
MX2007002606A (en) 2007-05-15
EP1786408A1 (en) 2007-05-23
EP1786408A4 (en) 2010-07-28
RU2007112114A (en) 2008-10-10
BRPI0514701A (en) 2008-06-24
WO2006024689A1 (en) 2006-03-09
AU2005279178A1 (en) 2006-03-09
KR20070059110A (en) 2007-06-11
JP2008511615A (en) 2008-04-17
CA2578852A1 (en) 2006-03-09

Similar Documents

Publication Publication Date Title
NO20071160L (en) Use of a selective estrogen receptor modulator for the preparation of a pharmaceutical composition for use in a method for the treatment or prevention of androgen deficiency
MA32200B1 (en) New formulations, tablets consisting of these formulas, their use and method of preparation
WO2009068689A3 (en) Combination of protein tyrosine phosphatase inhibitors and human growth hormone for the treatment of muscle atrophy and related disorders
NO20075660L (en) Composition for the treatment of inflammatory diseases
MX2009001711A (en) Sustained-release formulations of topiramate.
ATE453642T1 (en) SUBSTITUTED PHENYLAMINOPYRIMIDINES
WO2006015259A3 (en) Compounds and compositions as modulators of steroid hormone nuclear receptors
NO20092584L (en) Pharmaceutical compositions and their methods of use
MX2010004494A (en) Use of trkb antibodies for the treatment of respiratory disorders.
MX2010003550A (en) Multi-portion intra-oral dosage form with organoleptic properties.
NO20074999L (en) Method and preparation for the treatment of peripheral vascular diseases
EP2178869A4 (en) Indole compounds as an inhibitor of cellular necrosis
MX2020008616A (en) Sublingual fentanyl spray.
RS52199B (en) Pharmaceutical compositions of a neuroactive steroid and uses thereof
WO2007025005A3 (en) Sustained release formulations of nalbuphine
NO20100301L (en) Improved brimonidine compositions for the treatment of erythema
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
MX2015014656A (en) Sustained-release formulations of colchicine and methods of using same.
WO2006119389A3 (en) Quinine-containing controlled-release formulations
WO2007038506A3 (en) Method for the treatment of cachexia
WO2005077122A3 (en) Compounds and compositions as lxr modulators
NO20083836L (en) N hydroksyakrylamidforbindelser
NO20080936L (en) Transdermal drug delivery devices containing O-desmethylvenlafaxine (ODV) or salts thereof
NO20082047L (en) Slow release composition, process for its preparation and use thereof
NO20074332L (en) Method and preparation for the treatment of central nervous system disorders

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application